Anticholinergic burden: Clinical implications for seniors and strategies for clinicians

Consultant Pharmacist

Volumn 27, Issue 8, 2012, Pages 564-582

  Karimi, Sahar ^a   Dharia, Sheetal P ^b   Flora, Deanna S ^c   Slattum, Patricia W ^c  

^a KAISER PERMANENTE   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Adverse drug events; Anticholinergic; Antimuscarinic; Elderly; Geriatric; Older adult

Indexed keywords

AMITRIPTYLINE; CARISOPRODOL; CHLORPHENIRAMINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOZAPINE; CYCLOBENZAPRINE; DARIFENACIN; DICYCLOVERINE; DIPHENHYDRAMINE; DOXEPIN; HYDROXYZINE; HYOSCYAMINE; IMIPRAMINE; IPRATROPIUM BROMIDE; MUSCARINIC M1 RECEPTOR; MUSCARINIC M2 RECEPTOR; MUSCARINIC M3 RECEPTOR; MUSCARINIC M4 RECEPTOR; MUSCARINIC RECEPTOR BLOCKING AGENT; NEUROLEPTIC AGENT; OLANZAPINE; OXYBUTYNIN; PIRENZEPINE; SCOPOLAMINE; SOLIFENACIN; THIORIDAZINE; TIOTROPIUM BROMIDE; TOLTERODINE; TROSPIUM CHLORIDE; UNINDEXED DRUG;

AGED; AGING; AGITATION; AMNESIA; ANGINA PECTORIS; ANTICHOLINERGIC EFFECT; ANTICHOLINERGIC SYNDROME; ATAXIA; BLURRED VISION; CENTRAL NERVOUS SYSTEM; CHOLINERGIC SYSTEM; CLINICAL EVALUATION; COGNITIVE DEFECT; CONCENTRATION LOSS; CONFUSION; CONSTIPATION; DELIRIUM; DEMENTIA; DENTAL CARIES; DIZZINESS; DROWSINESS; DRUG CONTRAINDICATION; DRUG EFFECT; DRUG EXPOSURE; DRUG WITHDRAWAL; FATIGUE; FUNCTIONAL STATUS; GLAUCOMA; HALLUCINATION; HEALTH CARE PERSONNEL; HEALTH PRACTITIONER; HEART MUSCLE CONDUCTION DISTURBANCE; HEART RATE; HEAT STROKE; HIGH RISK POPULATION; HUMAN; HYPERTHERMIA; MEDLINE; MEMORY DISORDER; MOTION SICKNESS; MYDRIASIS; NONHUMAN; OUTCOME ASSESSMENT; OVERACTIVE BLADDER; PERIODONTAL DISEASE; PERIPHERAL NERVOUS SYSTEM; PERISTALSIS; PHARMACIST; POLYPHARMACY; PREVALENCE; QUALITY OF LIFE; REVIEW; RISK ASSESSMENT; RISK FACTOR; SIDE EFFECT; SPEECH DISORDER; STOMACH EMPTYING; STOMACH SECRETION; SUPRAVENTRICULAR TACHYCARDIA; SWEATING; TASTE DISORDER; URINARY HESITANCY; URINARY TRACT INFECTION; URINE INCONTINENCE; URINE RETENTION; XEROSTOMIA;

AGE FACTORS; AGED; CHOLINERGIC ANTAGONISTS; HUMANS; MEDICATION THERAPY MANAGEMENT; PHARMACEUTICAL SERVICES; PHARMACISTS; PROFESSIONAL ROLE;

EID: 84864579876     PISSN: 08885109     EISSN: None     Source Type: Journal    
DOI: 10.4140/TCP.n.2012.564     Document Type: Review

References (85)

1. Merchant RA, Li B, Yap KB et al. Use of drugs with anticholinergic effects and cognitive impairment in communityliving older persons. Age Ageing 2009;38:105-8.
2. Literature Review of Polypharmacy and Older Drivers: Identifying Strategies to Study Drug Usage and Driving Functioning Among Older Drivers 2006. Available at http://www.nhtsa.gov/people/injury/olddrive/druguse-olderdriver/ images/job%202859%20polypharmacy-new.pdf. Accessed July 1, 2011.
3. Tune LE. Anticholinergic effects of medication in elderly patients. J Clin Psychiatry 2001;62 (suppl 21:11-4).
4. Kay GG, Abou-Donia MB, Messer WS et al. Antimuscarinic drugs for overactive bladder and their potential effects on cognitive function in older adults. J Am Geriatr Soc 2005;53:2195-201. (Pubitemid 43001205)
5. Lechevallier-Michel N, Molimard M, Dartigues J et al. Drugs with anticholinergic properties and cognitive performance in the elderly: results from the PAQUID study. Br J Clin Pharmacol 2004;59 [?]2:143-51.
6. Volpicelli LA, Levey AI. Muscarinic acetylcholine receptor subtypes in cerebral cortex and hippocampus. Prog Brain Res 2004;145:59-66. (Pubitemid 37442934)
7. Anagnostaras SG, Murphy GG, Hamilton SE et al. Selective cognitive dysfunction in acetylcholine M1 muscarinic receptor mutant mice. Nat Neurosci 2003;6:51-8. (Pubitemid 36026332)
8. Seeger T, Fedorova I, Zheng F et al. M2 muscarinic acetylcholine receptor knock-out mice show deficits in behavioral flexibility, working memory, and hippocampal plasticity. J Neurosci 2004;24:10117-27. (Pubitemid 39492037)
9. Fienberg M. The problems of anticholinergic adverse effects in older patients. Drugs Aging 1993;3:335-48.
10. Staskin DR, MacDiarmid SA. Using anticholinergics to treat overactive bladder: the issue of treatment tolerability. Am J Med 2006;119:9S-15S. (Pubitemid 43227968)
11. Mintzer J, Burns A. Anticholinergic side-effects of drugs in elderly people. J R Soc Med 2000;93:457-62.
12. Kay GG, Granville LJ. Antimuscarinic agents: implications and concerns in the management of overactive bladder in the elderly. Clin Ther 2005;27:127-38. (Pubitemid 40342583)
13. Monane M, Avorn J, Beers M et al. Anticholinergic drug use and bowel function in nursing home patients. Arch Intern Med 1993;153:633-8. (Pubitemid 23072392)
14. Ray PG, Meador KJ, Loring DW et al. Central anticholinergic hypersensitivity in aging. J Geriatr Psychiatry Neurol 1992;5:72-7.
15. Zemishlany Z, Thorne AE. Anticholinergic challenge and cognitive functions: a comparison between young and elderly normal subjects. Isr J Psychiatry Relat Sci 1991;8:32-41.
16. Mulsant BH, Pollock BG, Kirshner M et al. Serum anticholinergic activity in a community-based sample of older adults. Arch Gen Psychiatry 2003;60:198-203.
17. Chew ML, Mulsant BH, Pollock BG et al. Anticholinergic activity of 107 medications commonly used in older adults. J Am Geriatr Soc 2008;56:1333-41.
18. Pollock BG. Anticholinergic effects in older adults. Weighing the risk-benefit ratio. Elder Care 2004;4:5-7.
19. Tune LE, Bylsma FW. Benzodiazepine-induced and anticholinergic-induced delirium in the elderly. Int Psychogeriatr 1991;3:397-408.
20. Mach JR Jr, Dysken MW, Kuskowski M et al. Serum anticholinergic activity in hospitalized older persons with delirium: a preliminary study. J Am Geriatr Soc 1995;43:491-5.
21. Flacker JM, Cummings V, Mach JR et al. The association of serum anticholinergic activity with delirium in elderly medical inpatients. Am J Geriatr Psychiatry 1998;6:31-41. (Pubitemid 28051719)
22. Kolanowski A, Fick DM, Campbell J et al. A preliminary study of anticholinergic burden and relationship to a quality of life indicator, engagement in activities, in nursing home residents with dementia. J Am Med Dir Assoc 2009;10:252-7.
23. Carnahan RM, Lund BC, Perry PJ et al. The anticholinergic drug scale as a measure of drug-related anticholinergic burden: associations with serum anticholinergic activity. J Clin Pharmacol 2006;46:1481-6. (Pubitemid 44704208)
24. Hilmer SN, Mager DE, Simonsick EM et al. A drug burden index to define the functional burden of medications in older people. Arch Intern Med 2007;167:781-7. (Pubitemid 46658335)
25. Hilmer SN, Mager DE, Simonsick EM et al. Drug burden index score and functional decline in older people. Am J Med 2009;122(:1142-9.e1-2.
26. Hamilton H, Gallagher P, Ryan C et al. Potentially inappropriate medications defined by STOPP criteria and the risk of adverse events in older hospitalized patients. Arch Intern Med 2011;171:1013-9.
27. Cupp M. PL Detail-Document, STARTing and STOPPing Medications in the Elderly 2011. Available at http://pharmacistsletter.therapeuticresearch.com/pl/ ArticleDD.aspx?cs=FACULTY&s=PL&pt=6&fpt=31&dd=270906&pb= PL&searchid=32337213. Accessed October 1, 2011.
28. Alagiakrishnan K, Wiens CA. Approach to drug induced delirium in the elderly. Postgrad Med J 2004;80:388-93. (Pubitemid 38961859)
29. Heuberger RA, Caudell K. Polypharmacy and nutritional status in older adults: a cross-sectional study. Drugs Aging 2011;28:315-23.
30. Catterson ML, Preskorn SH, Martin RL. Pharmacodynamic and pharmacokinetic considerations in geriatric psychopharmacology. Psychiatr Clin North Am 1997;20;205-18 (Pubitemid 27118615)
31. Scheife R, Masayuki T. Central nervous system safety of anticholinergic drugs for the treatment of overactive bladder in the elderly. Clin Ther 2005;27:144-53. (Pubitemid 40462007)
32. Milton JC, Hill-Smith I, Jackson SHD. Prescribing for older people. BMJ 2008;336:606-9. (Pubitemid 351439519)
33. Campbell NL, Boustani MA, Lane KA et al. Use of anticholinergics and the risk of cognitive impairment in an African American population. Neurology 2010;75:152-9.
34. Carriere I, Fourrier-Reglat A, Dartigues JF et al. Drugs with anticholinergic properties, cognitive decline, and dementia in an elderly general population. Arch Intern Med 2009;169:1317-24.
35. Chatterjee S, Mehta S, Sherer JT et al. Prevalence and predictors of anticholinergic medication use in elderly nursing home residents with dementia: analysis of data from the 2004 National Nursing Home Survey. Drugs Aging 2010;27:987-97.
36. Anderson D. Preventing delirium in older people. Br Med Bull 2005;73:25-34. (Pubitemid 43020356)
37. Han L, McCusker J, Cole M et al. Use of medications with anticholinergic effect predicts clinical severity of delirium symptoms in older medical inpatients. Arch Intern Med 2001;161:1099-105. (Pubitemid 32685536)
38. Lim CJ, Trevino C, Tampi RR. Can olanzapine cause delirium in the elderly? Ann Pharmacother 2006;40:135-8. (Pubitemid 43221486)
39. Ochs KL, Zell-Kanter M, Mycyk MB. Hot, blind, and mad: avoidable geriatric anticholinergic delirium. Am J Emerg Med 2011;Mar 31 [Epub ahead of print].
40. Caeiro L, Ferro JM, Claro MI et al. Delirium in acute stroke: a preliminary study of the role of anticholinergic medications. Eur J Neurol 2004;11:699-704. (Pubitemid 39389672)
41. McCusker J, Cole M, Bellavance F et al. The reliability and validity of a new measure of severity of delirium. Int Psychogeriatr 1998;10:303-8.
42. Ancelin ML, Artero S, Portet F et al. Non-degenerative mild cognitive impairment in elderly people and use of anticholinergic drugs: longitudinal cohort study. BMJ 2006;332:455-9.
43. Ehrt U, Broich K, Petter JP et al. Use of drugs with anticholinergic effect and impact on cognition in Parkinson's disease: a cohort study. J Neurol Neurosurg Psychiatry 2010;81:160-5.
44. Chapple CR, Khullar V, Gabriel Z et al. The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol 2008;54:543-62 [Epub 2008 Jun 20].
45. The American Geriatrics Society 2012 Beers Criteria Update Expert Panel. AGS updated Beers Criteria for potentially inappropriate medication use in older adults. Available at http://www.americangeriatrics.org/files/documents/beers/ 2012BeersCriteria-JAGS.pdf. Accessed July 9, 2012.
46. Gerretsen P, Pollock BG. Drugs with anticholinergic properties: a current perspective on use and safety. Expert Opin Drug Saf 2011;10:751-65.
47. Staskin D, Kay G, Tannenbaum C et al. Trospium chloride is undetectable in the older human central nervous system. J Am Geriatr Soc 2010;58:1618-9.
48. Staskin D, Kay G, Tannenbaum C et al. Trospium chloride has no effect on memory testing and is assay undetectable in the CNS of older patients with overactive bladder. Int J Clin Pract 2010;64:1294-300.
49. Jakobsen SM, Kersten H, Molden E. Evaluation of brain anticholinergic activities of urinary spasmolytic drugs using a highthroughput radio receptor bioassay. J Am Geriatr Soc 2011;59:501-5.
50. Norton C. Constipation in older patients: effects on quality of life. Br J Nurs 2006;15:188-92.
51. Hosia-Randell H, Suominen M, Muurinen S et al. Use of laxatives among older nursing home residents in Helsinki, Finland. Drugs Aging 2007;24:147-54. (Pubitemid 46327573)
52. Clemett D, Jarvis B. Tolterodine: a review of its use in the treatment of overactive bladder. Drugs Aging 2001;18:277-304. (Pubitemid 32391815)
53. Van Kerrebroeck P, Kreder K, Jonas U et al. Tolerotidine once daily: superior efficacy and tolerability in the treatment of overactive bladder. Urology 2001;57:414-21. (Pubitemid 32192963)
54. Diokno AC, Appell RA, Sand PK et al. Prospective, randomized, double-blind study of the efficacy and tolerability of the extendedrelease formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial. Mayo Clin Proc 2003;78:687-95. (Pubitemid 36665898)
55. Rovner ES, Wein AJ. Update on overactive bladder: pharmacologic approaches on the horizon. Curr Urol Rap 2003;4:385-90.
56. Hoflner K, Halaska M, Primus C et al. Tolerability and efficacy of trospium chloride in a long-term treatment (52 weeks) in patients with urge syndrome: a double-blind, controlled multicentre clinical trial. World J Urol. 2003;20:392-9. (Pubitemid 44175311)
57. Haab F, Stewart L, Dwyer P. Darifenacin, an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder. Eur Urol 2004;45:420.
58. Chapple CR, Martinez-Garcia R, Selvaggi L et al. A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. Eur Urol 2005;48:464.
59. Zinner N, Susset J, Gittelman M et al. Efficacy, tolerability and safety of darifenacin, an M(3) selective receptor antagonist: an investigation of warning time in patients with OAB. Int J Clin Pract 2006;60:119.
60. Kesten S, Jara M, Wentworth C et al. Pooled clinical trial analysis of tiotropium safety. Chest 2006;130:1695-703. (Pubitemid 46033421)
61. Keating GM. Tiotropium bromide inhalation powder: a review of its use in the management of chronic obstructive pulmonary disease. Drugs 2012 Jan 4 [Epub ahead of print].
62. Yohannes AM, Willgoss TG, Vestbo J. Tiotropium for treatment of stable COPD: a meta-analysis of clinically relevant outcomes. Respir Care 2011;56:477-87.
63. Cohen R, Wilkins KM, Ostroff R et al. Olanzapine and acute urinary retention in two geriatric patients. Am J Geriatr Pharmacother 2007;5:241-6. (Pubitemid 350063663)
64. Stephenson A, Seitz D, Bell CM et al. Inhaled anticholinergic drug therapy and the risk of acute urinary retention in chronic obstructive pulmonary disease. Arch Intern Med 2011;171:914-20.
65. Razeqhinejad MR, Myers JS, Katz LJ. Iatrogenic glaucoma secondary to mediations. Am J Med 2011;124:20-5.
66. Martin-Latry K, Goumy MP, Latry P et al. Psychotropic drugs use and risk of heat-related hospitalisation. Eur Psychiatry 2007;22:335-8. (Pubitemid 47391219)
67. Nebes RD, Pollock BG, Halligan EM et al. Serum anticholinergic activity and motor performance in elderly persons. J Gerontol Med Sci 2007;62A:83-5. (Pubitemid 46931552)
68. Cao YJ, Mager DE, Simonsick EM et al. Physical and cognitive performance and burden of anticholinergics, sedatives, and ACE inhibitors in older women. Clin Pharmacol Ther 2008;83:422-9. (Pubitemid 351272629)
69. Landi F, Russo A, Liperoti R et al. Anticholinergic drugs and physical function among frail elderly population. Clin Pharmacol Ther 2007;81:235-41. (Pubitemid 46174821)
70. Peterson JF, Kuperman GJ, Shek C et al. Guided prescription of psychotropic medications for geriatric inpatients. Arch Intern Med 2005;165:802-7. (Pubitemid 40569435)
71. Beers MH. Explicit criteria for determining potentially inappropriate medication use by the elderly: an update. Arch Intern Med 1997;157:1531-6. (Pubitemid 27305197)
72. Knight EL, Avorn J. Quality indicators for appropriate medication use in vulnerable elders. Ann Intern Med 2001;135:703-10. (Pubitemid 33015483)
73. Tollefson GD, Montague-Clouse J, Lancaster SP. The relationship of serum anticholinergic activity to mental status performance in an elderly nursing home population. J Neuropsychiatry Clin Neurosci 1991;3:314-9.
74. Castelino RL, Hilmer SN, Bajorek BV et al. Drug burden index and potentially inappropriate medications in community-dwelling older people. Drugs Aging 2010;27:135-48.
75. Nishtala PS, Hilmer SN, McLachlan AJ et al. Impact of residential medication management reviews on drug burden index in aged-care homes. Drugs Aging 2009;26:677-86.
76. Nye AM, Clinard VB, Barnes CL. Medication nonadherence secondary to drug-induced memory loss. Consult Pharm 2010;25:117-21.
77. Reuben DB, Herr KA, Pacala JT et al. Geriatrics at your fingertips online edition 2011. Available at www.geriatricsatyourfingertips.org. Accessed July 1, 2011.
78. Scott GN, Cupp M. Potentially harmful drugs in the elderly: Beers list and more 2007. Available at http://pharmacistsletter.therapeuticresearch.com/pl/ ArticleDD.aspx?nidchk=1&cs=FACULTY&s=PL&pt=6&fpt=31&dd= 230907&pb=PL&searchid=32337165. Accessed October 1, 2011.
79. Ness J, Hoth A, Barnett MJ et al. Anticholinergic medications in community-dwelling older veterans: prevalence of anticholinergic symptoms, symptom burden, and adverse drug events. Am J Geriatr Pharmacother 2006;4:42-51.
80. Zarowitz BJ, Stefanacci R, Hollenack K et al. The application of evidence-based principles of care in older persons (issue 5): Alzheimer's disease. J Am Med Dir Assoc 2007;8:183-93. (Pubitemid 46344865)
81. Rudolph JL, Salow MJ, Angelini MC et al. The anticholinergic risk scale and anticholinergic adverse effects in older persons. Arch Intern Med 2008;168:508-13. (Pubitemid 351547214)
82. Aizenberg D, Sigler M, Weizman A et al. Anticholinergic burden and the risk of falls among elderly psychiatric inpatients: a 4-year case-control study. Int Psychogeriatr 2002;14:307-10. (Pubitemid 35375545)
83. Han L, Agostini JV, Allore HG. Cumulative anticholinergic exposure is associated with poor memory and executive function in older men. J Am Geriatr Soc 2008;56:2203-10.
84. Rochon PA, Gurwitz JH. Optimising drug treatment for elderly people: the prescribing cascade. BMJ 1997;315:1096.
85. Spinewine A, Schmader KE, Barber N et al. Appropriate prescribing in elderly people: how well can it be measured and optimised? Lancet 2007;370:173-84. (Pubitemid 47049724)